CVS-Aetna Merger Will Create Powerful Player in Healthcare
CVS looks undervalued today and has some great competitive advantages.
Vishnu Lekraj: Late last year, CVS and Aetna announced they were going to merge into a large healthcare services conglomerate. There has been much talk in the market about this new firm, how it will flow, and what the moat implications will be for the company ultimately.
After analyzing the deal and looking at it from the perspective of healthcare servicing in the U.S. moving forward over the next several decades, we believe this company will be a powerful player within this space. We believe it will command a lot of pricing power and a lot of leverage within the market that will give it some cost advantages over its peers, such as the managed-care firms, the PBMs, and retail pharmacies.
Vishnu Lekraj does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.